RT Journal Article
SR Electronic
A1 Sinclair, Heather Q.
T1 Rosiglitazone and New Insights in the BARI 2D Trial
JF MD Conference Express
YR 2010
FD SAGE Publications
VO 10
IS 6
SP 24
OP 25
DO 10.1177/155989771006008
UL http://mdc.sagepub.com/content/10/6/24.abstract
AB According to post hoc analyses of the Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes [BARI 2D; NCT00006305] data, rosiglitazone is not associated with an increased risk of major adverse cardiovascular events, including myocardial infarction and death, in patients with type 2 diabetes mellitus and established coronary artery disease.